Dr. Agarwal's Health Care Limited has informed the Exchange about Investor Presentation
AGARWALEYE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Dr. Agarwal's Health Care, India's largest eye care services chain by revenue, reported FY26 total income of ₹2,125 Cr (20.9% YoY growth) and EBITDA of ₹614 Cr (22.2% YoY growth) with EBITDA margins at 28.9%. PAT came in at ₹168 Cr, up 52.4% YoY with margins expanding to 7.9% from 6.3% in FY25. The company operates 288 eye care facilities across India and Africa, having added 57 new facilities during FY26 (roughly one per week). Same store sales growth was strong at 14.1% for facilities set up up to FY23. The hub-and-spoke model includes 89 primary, 164 secondary, and 35 tertiary facilities. Revenue mix is dominated by surgeries (66.7%), followed by diagnostics/consultations (13%), opticals (11.9%), and pharma (8.4%). Regional expansion plans indicate 60 facilities planned for FY27 split evenly between H1 and H2. The company maintains a net cash position with strong operating cash flows.
Strong operational and financial performance with PAT growth outpacing revenue growth, indicating improving profitability. The aggressive facility expansion (57 additions in FY26, 60 planned for FY27) provides growth visibility. However, EBITDA margins at 28.9% remain below FY24's peak of 29.5%, suggesting margin pressure from expansion costs.